Partenariats industriels

Les partenariats industriels contribuent à la réussite du développement technologique, convertissant une invention en produit à succès au service des patients et de la santé publique. L’Institut Pasteur et ses partenaires industriels œuvrent conjointement à la réalisation de cet objectif.

Contact us

Please contact us

Licensing Opportunities

The currently available patents for licensing and tech transfer are listed below. Please consult this document for further details of technologies potentially meeting your needs.

R&D Collaborations

The combination of our scientific expertise and industrial awareness will enable you to identify innovative solutions to meet your challenges.

Other Contracts

By partnering with the Institut Pasteur, you will benefit from access to science, knowledge, skills and cutting-edge infrastructure.

Openness to future industrial partners

Bringing innovative solutions to patients’ unmet needs is a challenge that no single organization is currently capable of achieving. Academic and industrial stakeholders must now rapidly unite their expertise to provide medical, scientific, and technological responses for patient health.
Following its successful involvement in past and current research partnerships, the Institut Pasteur is now intensifying its visibility and availability to attract new industrial partners, from startups to major groups.

Research and Development collaborations

Industrial property - Innovation - Institut Pasteur

The Institut Pasteur's intellectual property strategy is characterized by several dominant patents.

In the early 1980s, the Institut Pasteur started protecting pioneering biotechnology inventions with patents:

production of the yeast-derived hepatitis B vaccine (still marketed by GSK and Merck),
inventions based on the identification and molecular characterization of the HIV-1 and HIV-2 viruses,
various high-risk HPV strains.

These initial major patents were followed by other dominant patents protecting previously unknown methods such as:

homologous recombination,
cold probes,
meganucleases,
lentiviral technology,
the vaccine platform based on the measles vector.

What the Institut Pasteur offers

By collaborating with the Institut Pasteur, industry partners can benefit from its extensive range of research fields.

Joint applications to national and international calls for proposals (IMI, H2020, NIH, CEPI, etc.)
A 60% research tax credit for which all companies involved in R&D in France are eligible
Access to the Institute’s cutting-edge technical facilities, such as the Technological Research Platforms (DTPS), Bioinformatics and Biostatistics Hub, Medical Center, and Center for Translational Science (CRT), as well as the Microbiology Technology Institute Bioaster
Expertise
And much more if you are part of a strategic alliance partnership

Post-contract Management

In order to address the challenges of product development costs associated with the high failure rate of development collaborations, the Industrial Agreements Office builds trustworthy, long-term relationships with industrial partners in full transparency.

Bioaster

Founded in April 2012 by the Institut Pasteur and Lyonbiopole health competitiveness cluster, following the initiative of the French government, Bioaster Technology Research Institute (TRI) is working to develop a unique technological and innovative model to help face the latest challenges in microbiology, and in particular to:

Fight antimicrobial resistance
Improve the safety and efficacy of vaccines. Quickly diagnose infections at the patient’s bedside. Take full advantage of human and animal microbiota.

The aim of Bioaster is to boost the development of medical and nutritional solutions for human and animal health.

Bioaster is supported by high-profile academic and industrial partners. Since it was set up, it has coordinated over 53 research projects with 25 academic partners and 26 industry partners (source: Bioaster).

Between the phases of knowledge acquisition and providing a solution for the patient, Bioaster seeks to act as a bridge between the academic and private spheres, provide technological added value in microbiology, and is an agile and collaborative organization that reduces the risks associated with innovation.

Visit the website